Biotherapeutics News and Research

RSS

Cancer Research UK invests £14 million to transform London into cancer biotherapeutics hub

The city of London will be transformed into a world leading hub for cancer biotherapeutics research and treatment, with a new £14 million investment from Cancer Research UK, announced today (Monday).

19 Sep 2018

New polyclonal immunotherapy successfully neutralizes Ebola virus

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided "100% protection against a lethal dose of the Ebola virus" in a recent animal study published in The Journal of Infectious Diseases.

15 Aug 2018

Oncolytic virus alerts the immune system to attack tumors

A new UC San Francisco study has shown that a cancer-killing virus currently in clinical trials may function as a cancer vaccine - in addition to killing some cancer cells directly, the virus alerts the immune system to the presence of a tumor, triggering a powerful, widespread immune response that kills cancer cells far outside the virus-infected region.

14 Feb 2018

UTokyo enters into agreement for developing personalized cancer vaccine

The University of Tokyo entered an agreement for developing a personalized cancer vaccine using a novel method involving the body's immune response.

25 Jan 2018

TGen awarded $2.5 million SU2C grant to test new method of treating pancreatic cancer

Stand Up To Cancer has awarded a $2.5 million SU2C CatalystR grant to the Translational Genomics Research Institute to investigate a revolutionary new method of treating pancreatic cancer, one of the most aggressive of all cancers.

13 Oct 2017

New cell therapy restores movement in people with paralyzing spinal cord injuries

Four of six people with paralyzing spinal cord injuries who were treated with a new cell therapy have recovered two or more motor levels on at least one side, new study results show.

6 Oct 2017

Nanomedical Diagnostics introduces new NTA biosensor for faster, reliable characterization of proteins

Nanomedical Diagnostics, a cutting-edge life science company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of a new NTA biosensor chip for use with its label-free Agile R100 assay system.

26 Jul 2017

Pharmaceutical giant Roche funds concept study aiming to find cure for Angelman syndrome

A collaborative group of parent-driven organizations seeking a cure for Angelman syndrome has teamed up with F. Hoffmann-La Roche Ltd, one of the world’s largest pharmaceutical and diagnostics companies, in the first phase of a study that will support the design of human clinical trials and treatment development for the disorder.

28 Jun 2017

WHO to launch pilot project for prequalifying biosimilar cancer medicines

This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.

8 May 2017

Research shows how Ebola viral proteins packaged in exosomes affect immune cells

Cells infected by the deadly Ebola virus may release viral proteins such as VP40 packaged in exosomes, which, as new research indicates, can affect immune cells throughout the body impairing their ability to combat the infection and to seek out and destroy hidden virus.

16 Mar 2017

New therapeutic agent shows potential for treating optic neuritis linked to multiple sclerosis

A new therapeutic agent tested in a mouse model of multiple sclerosis (MS) produced anti-inflammatory activity and prevented loss of cells in the optic nerve, according to a new study by researchers in the Perelman School of Medicine at the University of Pennsylvania, with Pittsburgh-based Noveome Biotherapeutics.

9 Feb 2017

New therapy to treat spinal cord injuries shows improvements in motor function

A new therapy to treat spinal cord injuries in people who have lost all motor and sensory function below the injury site shows additional motor function improvement at 6-months and 9-months following treatment with 10 million AST-OPC1.

24 Jan 2017

Blocking critical molecule with therapeutic antibody could effectively reduce leukemia burden

Acute myeloid leukemia (AML) is an aggressive cancer known for drug resistance and relapse. In an effort to uncover new treatment strategies, researchers at University of California San Diego School of Medicine and Moores Cancer Center discovered that a cell surface molecule known as CD98 promotes AML.

27 Oct 2016

AXT to exclusively distribute Unchained Labs biologics research tools in Australia, New Zealand

AXT is excited to announce that they have partnered with Unchained Labs and will now be exclusively distributing their innovative and novel range of instruments for the analysis and formulation of biologics in Australia and New Zealand.

From AXT Pty Ltd 20 Sep 2016

Clinical trial assesses efficacy of experimental treatment in individuals with cervical spinal cord injury

Physicians at Rush University Medical Center became the first in Illinois to inject AST-OPC1 (oligodendrocyte progenitor cells), an experimental treatment, into the damaged cervical spine of a recently paralyzed man as part of a multicenter clinical trial.

14 Sep 2016

Novel Trojan Horse antibody strategy may target Ebola's Achilles' heel

In research published online today in Science, a team of scientists describe a new therapeutic strategy to target a hidden Achilles' heel shared by all known types of Ebola virus.

8 Sep 2016

CPhI Pre-Connect Congress to provide insights on major developments in pharmaceutical industry

CPhI Worldwide, organized by UBM EMEA, announces the upcoming trends in the 8th edition of the CPhI Pre-Connect Congress, taking place on October 3rd.

26 Aug 2016

New topical film patch can effectively close dermal wounds, reduce scarring

Currently there is no product available based on polymer film containing active molecules to accelerate dermal wound healing that also reduces the scar formation.

8 Jul 2016

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

Asterias Biotherapeutics, Inc. today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for AST-VAC1, its investigational therapy targeting acute myeloid leukemia (AML).

24 Feb 2016

New treatment protects mice from MERS infection

In a new study, University of Maryland School of Medicine researchers have had promising results with a new treatment for Middle East Respiratory Syndrome (MERS). The study, published today in the journal Science Translational Medicine, found a new treatment that protected mice from MERS infection.

18 Feb 2016